publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Greek Characters a-hemolytic streptococci, 238t, 244-245 b-hemolytic streptococci, 107, 126, 237, 238t, 244-245, 422 b-lactam antibiotics, 257, 581 g-aminobutyric acid (GABA), 112 A A-modified live-virus attenuated vaccines. See ARVACs (A-modified live-virus attenuated vaccines). ABC (avidin-biotin) complex, 160-161 ABCD (amphotericin B collodial dispersion), 408 Abdominal abscesses, 286 Abdominal disease, 286 ABG (arterial blood gas) assessments, 292-293, 374-375 ABLC (amphotericin B lipid complex), 408. See also AMB (amphotericin B). Abortion, 92-98, 93f, 95f-96f, 150. See also Reproductive tract infections. ascendant placentitis and, 92-94 brucellosis and, 348-350. See also Brucellosis. diagnostic approaches to, 96-97 EHVs and, 150 infectious causes of, 92-98, 93f, 95f-96f leptospirosis and, 304-307 placentitis. See Placentitis. salmonellosis and, 339. See also Salmonellosis. viral causes, 97-98 Abscesses and abscessation, 7, 37-38, 55-57, 248-254, 249f, 252, 265, 286 abdominal, 286 aortic root, 37-38 cerebral, 248-249, 249f external, 265 intracranial, 55-56 lymph node, 252-253 metastatic, 252 pulmonary, 7 spinal, 56-57 streptococcal infections and, 248-254. See also Streptococcal infections. Absidia spp., 85, 417-418 Accessory gland infections, 100-101 Accidental ectoparasites, 509. See also Ectoparasites. ACE (angiotensin-converting enzyme) inhibitors, 28 Acepromazine, 379t Acholeplasma spp., 85 Acid-fast staining, 236, 238f, 450f Acidosis, 37-38 Acinetobacter spp., 106-107 Acquired immunodeficiency syndrome. See AIDS (acquired immunodeficiency syndrome). Acremonium spp., 386b Actinobacillus spp., 21-22, 71t, 237t, 238b, 345, 578 Actinomyces spp., 1-2, 85, 237t, 238b, 242-243, 382-384, 382t, 386b Active immunization, 294-295, 556-561, 557t, 559t Acute diarrhea, 42-43 Acute-phase responses, 324 Acute piroplasmosis, 469 Adaptive immunity responses, 128 ADD (agar disk diffusion), 242-243, 391, 579 Adenoviruses. See EADVs (equine adenoviruses). Adhesions, 286 Adjuvants, vaccines, 600-601. See also Vaccines. Adverse reactions, antimicrobials, 585-586, 585t Aedes spp., 506 Aflatoxins, 420-425 African horse sickness. See AHS (African horse sickness) and AHSV (African horse sickness virus). Agalactia, 251 Agar, 123-124, 242-243, 289, 391, 434, 474-475 agar disk diffusion. See ADD (agar disk diffusion). agar gel immunodiffusion tests. See AGID (agar gel immunodiffusion) tests. Agglutination, latex, 390-391 AGID (agar gel immunodiffusion) tests, 123-124, 289, 434, 474-475. See also ID (immunodiffusion). AHS (African horse sickness) and AHSV (African horse sickness virus), 111, 164-171 clinical findings for, 166-168, 166f-167f dikkop (cardiac) form, 166-167, 169-170 dunkop (pulmonary) form, 166, 168-169 horsesickness fever, 168 mixed form, 167-168, 170 diagnoses for, 168 epidemiology of, 165-166 etiology of, 164-165 pathogenesis of, 166, 166f pathologic findings for, 168-170, 168f-170f prevention of, 170-171 public health considerations for, 171 therapies for, 170 AIDS (acquired immunodeficiency syndrome), [393][394][395] 421, 432 Alkaloids, vinca, 605 Alopecia,[79][80] 278f, 410, 410f, 238t,[244][245] 111,[191][192][193][194][195][196][197] 111 clinical findings for, 195 diagnoses for,[195][196][191][192][193][194][195][196][197][192][193][194][195][191][192] 192t pathogenesis of, 195 pathologic findings for, 196 prevention of, 197 public health considerations for, 197 therapies for,[196][197][191][192][193][194][195][196][197][191][192][193][194][195][196][197][106][107] 386b, 420 Alveolar macrophage, 1-2 Index 621 Page numbers followed by b indicate boxes; f, figures; t, tables. AMA (anterior mesenteric artery), 481-482 Amantadine, 132-133 AMB (amphotericin B), 91t, 391, 402-408, 423-426, 427t, 434 Amblyomma spp., 500-501 Ambulatory practices, 538 Amicarbalide, 472 Amikacin sulfate, 64t, 76-77, 76t, 91t Aminoglycosides, 106, 580, 588-589 Ammonium chloride, 106 Ammonium sulfate, 106 Amphotericin B. See AMB (amphotericin B). Amphotericin B collodial dispersion. See ABCD (amphotericin B collodial dispersion). Amphotericin B lipid complex. See ABLC (amphotericin B lipid complex). Ampicillin, 27-38, 64t, 76-77, 76t, 91t, 106, 312, 414 Amplicons, 118 Amplification, nucleic acid, 117-120, 118f Amycolatopsis spp., 94 Anaerobic infections, 238-239, 381-384 anaerobes, 240b, 578-579 miscellaneous, 381-384 clinical signs of, 382-383 diagnoses for, 383 epidemiology of, 381-382, 382t etiology of, 381 pathogenesis of, 382-383 public health considerations for, 384 therapies for, 383-384 suspected, 238-239 Anaplasma phagocytophilum, 112, 241-244, 310, 354-357 infections of, 354-357 clinical findings for, 355-356, 355f-356f diagnoses of, 356 EGE agents and, 354-357 epidemiology of, 354 etiology of, 354 HGE agents and, 354-357 Ixodes pacificus and, 354 Ixodes ricinus and, 354 